IM Therapeutics develops HLA-directed immunotherapeutics that specifically inhibit the action of human leukocyte antigens involved in autoimmune responses. Their targeted therapies aim to address the underlying mechanisms of autoimmune diseases, with early efficacy demonstrated in type 1 diabetes.
Funding
$17.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune diseases often broadly suppress the immune system, leading to increased risk of infection and other side effects. These treatments do not address the underlying genetic factors driving the autoimmune response, leaving a significant unmet need for targeted therapies.
Solution
IM Therapeutics is developing a platform of HLA-directed immunotherapeutics designed to selectively inhibit the action of specific human leukocyte antigens (HLAs) implicated in autoimmune diseases. Their approach utilizes computational algorithms and 3-D modeling to screen millions of drug-like molecules for their ability to bind within specific domains of an HLA protein. This in silico platform predicts selectivity and enables rational drug design for optimal HLA blockade. The resulting drug candidates are characterized using in vitro and in vivo assays to confirm HLA-targeted activity.
Target Audience
The primary target audience includes individuals with autoimmune diseases such as Type 1 Diabetes and Celiac Disease, as well as pharmaceutical companies seeking novel, targeted immunotherapies.
Features
- Computational platform screens drug-like molecules for HLA-binding affinity and selectivity
- Rational drug design based on 3-D models of HLA protein domains
- In vitro and in vivo assays validate HLA-targeted activity
- Lead drug (IMT-002) in Phase 1b clinical trials for Type 1 Diabetes
- Pipeline of targeted therapies across multiple autoimmune diseases, including Celiac Disease